Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: finasteride

« Back to Dashboard

Finasteride is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Accord Hlthcare Inc, Actavis Totowa, Aurobindo Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Gedeon Richter Usa, Hetero Labs Ltd Iii, Ivax Sub Teva Pharms, Mylan, Mylan Pharms Inc, Sun Pharma Global, Teva, Zydus Pharms Usa Inc, and Merck, and is included in twenty-one NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for finasteride. Three suppliers are listed for this compound.

Summary for Generic Name: finasteride

Tradenames:3
Patents:3
Applicants:16
NDAs:21
Drug Master File Entries: see list13
Suppliers: see list3
Therapeutic Class:Genitourinary Agents
Hormonal Agents, Suppressant (Sex Hormones/Modifiers)

Pharmacology for Ingredient: finasteride

Clinical Trials for: finasteride

An Observational Registry-Based Study of a Potential Link Between Finasteride (MK-0906) and Male Breast Cancer in 4 Nordic Countries (MK-0906-162/2003.021)
Status: Active, not recruiting Condition: Male Breast Cancer

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy
Status: Completed Condition: Enlarged Prostate

Finasteride for Chronic Central Serous Chorioretinopathy
Status: Terminated Condition: Retinal Disease

Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition
Status: Completed Condition: Healthy

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition
Status: Completed Condition: Healthy

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions
Status: Completed Condition: Healthy

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Status: Completed Condition: Retinal Disease

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions
Status: Completed Condition: Healthy

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Status: Completed Condition: Retinal Disease

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
Status: Terminated Condition: Hematuria; Hematospermia

On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)
Status: Withdrawn Condition: Benign Prostatic Hyperplasia

Kinetics of the Finasteride Prostate Induced Apoptosis
Status: Active, not recruiting Condition: Benign Prostatic Hyperplasia

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
Status: Active, not recruiting Condition: Adenocarcinoma of the Prostate; Stage II Prostate Cancer

Testosterone Plus Finasteride Treatment After Spinal Cord Injury
Status: Not yet recruiting Condition: Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male

PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination
Status: Completed Condition: Benign Prostatic Hyperplasia (BPH)

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
Status: Completed Condition: Androgenetic Alopecia

A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
Status: Not yet recruiting Condition: Detectable Prostate Nodules

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Status: Terminated Condition: Benign Prostatic Hyperplasia

Topical Finasteride in the Treatment of Idiopathic Hirsutism
Status: Completed Condition: Idiopathic Hirsutism

Finasteride 5 mg Tablets, Non-fasting
Status: Completed Condition: Healthy

Finasteride 5 mg Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
Status: Recruiting Condition: Non-small Cell Lung Cancer

Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Status: Completed Condition: Androgenetic Alopecia

Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss
Status: Completed Condition: Androgenetic Alopecia

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
Status: Active, not recruiting Condition: Benign Prostate Hyperplasia

Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg
Status: Completed Condition: Healthy

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg
Status: Completed Condition: Healthy

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer

High Risk Prostate Cancer Prevention Study
Status: Completed Condition: Prostate Cancer

Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
Status: Completed Condition: Prostatic Hyperplasia

5-Alpha Reductase and Anabolic Effects of Testosterone
Status: Active, not recruiting Condition: Male Hypogonadism; Muscle Atrophy; Benign Prostate Hypertrophy; Sarcopenia

Oral T7 Oral Testosterone in Man
Status: Completed Condition: Healthy Males; Male Contraceptive

Finasteride, Dutasteride and Insulin Action
Status: Recruiting Condition: Healthy Volunteers

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
Status: Completed Condition: Benign Prostatic Hyperplasia; Enlarged Prostate

Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
Status: Completed Condition: Androgenetic Alopecia

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

ORAL T-6: Oral Androgens in Man-6
Status: Completed Condition: Contraception; Hypogonadism

Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)
Status: Completed Condition: Benign Prostatic Hypertrophy

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
Status: Completed Condition: Benign Prostatic Hyperplasia (BPH); Enlarged Prostate

Medical Therapy of Prostatic Symptoms (MTOPS)
Status: Completed Condition: Prostatic Hyperplasia; Prostatic Hypertrophy, Benign

Minimally Invasive Surgical Therapy for BPH
Status: Terminated Condition: Benign Prostatic Hyperplasia

A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia
Status: Active, not recruiting Condition: Androgenetic Alopecia

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
Status: Enrolling by invitation Condition: Benign Prostatic Hyperplasia

UGYTEX® Mesh Versus Subvesical Plication in the Surgical Treatment of Bladder Prolapse
Status: Recruiting Condition: Cystocele

Hormone Therapy in Treating Patients With Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer; Sexual Dysfunction and Infertility

Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
Status: Completed Condition: Prostatic Hyperplasia

Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
Status: Completed Condition: Benign Prostatic Hyperplasia

Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
Status: Completed Condition: Prostatic Hyperplasia

Pharmacogenomic Study of Androgenetic Alopecia
Status: Not yet recruiting Condition: Androgenetic Alopecia

Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Status: Completed Condition: Prostatic Hyperplasia

Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
Status: Completed Condition: Prostatic Hyperplasia

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
Status: Completed Condition: Benign Prostatic Hyperplasia

Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database
Status: Completed Condition: Prostatic Hyperplasia

S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT
Status: Terminated Condition: Prostate Cancer

Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
Status: Active, not recruiting Condition: Androgenetic Alopecia

Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia
Status: Completed Condition: Androgenic Alopecia

Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
Status: Completed Condition: Prostatic Hyperplasia

Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
Status: Completed Condition: Prostatic Hyperplasia

Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
Status: Completed Condition: Prostatic Hyperplasia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc
FINASTERIDE
finasteride
TABLET;ORAL078900Dec 28, 2009RXNo<disabled><disabled>
Merck
PROSCAR
finasteride
TABLET;ORAL020180Jun 19, 1992RXYes5,942,519<disabled><disabled>
Teva
FINASTERIDE
finasteride
TABLET;ORAL076511Dec 15, 2006RXNo<disabled><disabled>
Merck
PROPECIA
finasteride
TABLET;ORAL020788Dec 19, 1997RXYes5,571,817<disabled><disabled>
Mylan Pharms Inc
FINASTERIDE
finasteride
TABLET;ORAL078161Nov 5, 2013RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc